View Older Stories View More Recent Stories

Dec 16, 2024 07:30AM Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Dec 2, 2024 07:30AM HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Nov 19, 2024 07:30AM Soligenix (SNGX) Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Nov 19, 2024 07:30AM Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Nov 15, 2024 07:30AM Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
Nov 14, 2024 07:15AM Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Nov 8, 2024 07:30AM Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
Oct 24, 2024 07:30AM Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
Oct 22, 2024 07:31AM Soligenix (SNGX) Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Oct 22, 2024 07:30AM Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Oct 16, 2024 07:30AM Soligenix Invited to Present at Upcoming Investor Conferences
Oct 7, 2024 07:30AM HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
Oct 3, 2024 07:30AM Soligenix (SNGX) Announces Partnership with Sterling Pharma Solutions
Oct 3, 2024 07:30AM Soligenix Announces Partnership with Sterling Pharma Solutions
Sep 20, 2024 09:00AM Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Sep 16, 2024 07:30AM Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
Sep 3, 2024 07:31AM Soligenix (SNGX) Receives European Patent for Improved Production of Synthetic Hypericin
Sep 3, 2024 07:30AM Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
Aug 16, 2024 09:00AM Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Aug 9, 2024 07:30AM Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
Jul 15, 2024 10:16AM PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
Jul 9, 2024 08:21AM Soligenix(SNGX): Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Jul 9, 2024 07:30AM Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Jun 25, 2024 07:31AM Soligenix (SNGX) Announces Positive Results from a Comparative Study of HyBryte Against Valchlor
Jun 25, 2024 07:30AM Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
Jun 14, 2024 07:30AM A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
Jun 7, 2024 09:00AM Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Jun 5, 2024 08:00AM Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
May 31, 2024 07:30AM Soligenix, Inc. (SNGX) Announces Reverse Stock Split
May 31, 2024 07:30AM Soligenix Announces Reverse Stock Split
May 29, 2024 07:30AM Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
May 24, 2024 07:30AM Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
May 23, 2024 07:30AM Soligenix (SNGX) Encourages Stockholders to Vote "FOR" Reverse Stock Split
May 23, 2024 07:30AM Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
May 21, 2024 12:35PM PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
May 21, 2024 07:30AM SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
May 20, 2024 07:30AM Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
May 16, 2024 07:30AM Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
May 10, 2024 07:30AM Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
May 6, 2024 07:30AM Soligenix to Present at Upcoming Conferences
Apr 25, 2024 07:30AM Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
Apr 15, 2024 07:30AM Soligenix, Inc. (SNGX) Announces FDA Grants Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Apr 15, 2024 07:30AM FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Apr 11, 2024 07:32AM Soligenix (SNGX) Granted FDA Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Apr 11, 2024 07:30AM FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Apr 3, 2024 07:31AM Soligenix (SNGX) Enters Agreement with EMA on Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte
Apr 3, 2024 07:30AM Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
Mar 15, 2024 07:30AM Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
Feb 8, 2024 07:31AM Soligenix, Inc. (SNGX) Forms Behçet's Disease Medical Advisory Board
Feb 8, 2024 07:30AM Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
View More Recent Stories View Older Stories